Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "US-Government"

32 News Found

Vivimed Labs to manufacture, market Favipiravir tablets
News | May 11, 2021

Vivimed Labs to manufacture, market Favipiravir tablets

The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India

Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda
News | February 26, 2021

Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda

The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.

Latest Stories

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging